Impavido approved to treat tropical parasitic disease

(HealthDay)—Impavido (miltefosine) has been approved by the U.S. Food and Drug Administration to treat adults with leishmaniasis, a tropical disease caused by a parasite that's transmitted by the bites of sand flies.

Most Americans who contract the disease do so traveling overseas, the agency said in a news release.

The drug's safety and effectiveness were evaluated in clinical trials involving more than 700 people. Impavido's label will include a boxed warning that the medication could harm a developing fetus and shouldn't be taken by pregnant women.

Common side effects include nausea, vomiting, diarrhea, headache, loss of appetite, dizziness, , itching, fatigue and elevated liver enzymes, the FDA said.

The drug is produced by Paladin Therapeutics, based in Montreal.

More information: The U.S. Centers for Disease Control and Prevention has more about leishmaniasis

add to favorites email to friend print save as pdf

Related Stories

Vimizim approved for rare childhood disorder

Feb 17, 2014

(HealthDay)—Vimizim (elosulfase alfa) has been approved by the U.S. Food and Drug Administration to treat a rare childhood disorder called Mucopolysaccharidosis Type IVA, also known as Morquio A syndrome.

Northera approved for rare blood pressure condition

Feb 19, 2014

(HealthDay)—Northera (droxidopa) has been approved by the U.S. Food and Drug Administration to treat a rare, chronic condition characterized by a sudden drop in blood pressure when a person stands.

Opsumit approved for pulmonary arterial hypertension

Oct 23, 2013

(HealthDay)—Opsumit (macitentan) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a debilitating disease characterized by high blood pressure in the lung arteries.

Adempas approved to treat pulmonary hypertension

Oct 09, 2013

(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.

Pomalyst approved for advanced multiple myeloma

Feb 09, 2013

(HealthDay)—Pomalyst (pomalidomide) has been approved by the U.S. Food and Drug Administration to treat cases of multiple myeloma that have not responded to other therapies.

Recommended for you

Experts want restrictions on testosterone drug use (Update)

Sep 17, 2014

Federal health experts said Wednesday there is little evidence that testosterone-boosting drugs are effective for treating common signs of aging in men and that their use should be narrowed to exclude millions of Americans ...

User comments